Could common inflammation drug delay HIV's return?

This study tests whether baricitinib, a drug that reduces inflammation, can delay the return of HIV after people stop their regular antiretroviral therapy. Researchers will give 20 adults with well-controlled HIV the drug alongside their usual treatment for 26 weeks, then have them take only baricitinib after stopping their HIV medications. The main goal is to see if this approach safely extends the time before HIV levels rise enough to require restarting treatment.